Psoriasis

 

Below is a list of our psoriasis studies that are currently enrolling.

A Phase 3, Randomized, Active-controlled Study of Risankizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

  • Population: Individuals aged twelve to seventeen years old
  • Study Condition: Moderate to severe plaque psoriasis
  • Study Design: The purpose of this study is to evaluate the pharmacokinetics (how the study drug moves through the body), safety, and effectiveness of investigational drug risankizumab in a pediatric population with moderate to severe plaque psoriasis. Subjects that meet all eligibility criteria will be randomized 2:1 to receive either risankizumab or ustekinumab, an active control. Both drugs will be injected subcutaneously (underneath the skin). At Week 16, subjects receiving ustekinumab or who are unresponsive to risankizumab, will be switched to or continue to receive risankizumab. Subjects that are responsive to risankizumab at Week 16, will be re-randomized 1:1 to continue risankizumab or withdraw from the study drug. Subjects randomized to withdraw will receive no study drug until a flare occurs, after which they will enter a 16-week re-treatment study period.
  • Compensation will be provided

 

Please contact Dr. Caroline Porter for more information regarding ongoing psoriasis studies. 

 

Email: portecar@musc.edu

Phone: (843) 876-0110